FDA

From Nano World Order - Wiki
FDA headquarters, Silver Spring, Maryland

The Food and Drug Administration (FDA) is a federal agency of the United States government operating under the Department of Health and Human Services (HHS). Its stated mandate is to protect and promote public health through the regulation and supervision of food safety, pharmaceutical drugs, medical devices, biological products (including vaccines), cosmetics, and tobacco products. Established in its modern form by the Federal Food, Drug, and Cosmetic Act of 1938 — with roots going back to the Pure Food and Drug Act of 1906 — the FDA is headquartered in Silver Spring, Maryland, and is considered one of the most powerful regulatory agencies in the world. Its decisions directly affect billions of people globally, making questions about its independence, integrity, and transparency subjects of intense scrutiny.

Structure and Mandate

File:The Hoyes of Maryland.djvu The FDA is organised into several major centres, each responsible for a distinct regulatory domain:

  • Center for Drug Evaluation and Research (CDER) — oversees the approval of prescription and over-the-counter drugs, including clinical trial requirements and post-market surveillance.
  • Center for Biologics Evaluation and Research (CBER) — regulates biological products including vaccines, blood products, and gene therapies. CBER played a central role in the authorisation of COVID Vaccines during the 2020–2022 period.
  • Center for Devices and Radiological Health (CDRH) — oversees medical devices ranging from pacemakers and diagnostic tests to implantable Brain-Computer Interface technologies.
  • Center for Food Safety and Applied Nutrition (CFSAN) — regulates food labelling, additives, and safety standards.
  • Office of Regulatory Affairs (ORA) — conducts inspections and enforces compliance.

The FDA formally operates under HHS but exercises considerable independent authority. It receives funding both from congressional appropriations and from user fees paid directly by the pharmaceutical industry — a structural arrangement that has been widely criticised as a potential source of institutional conflict of interest.

The agency's decisions carry international weight: many foreign regulators, including the EMA (European Medicines Agency), closely follow FDA rulings when making their own approval determinations.

Regulatory Capture

The FDA seal, representing the regulatory authority at the center of industry-agency dynamics and capture debates.


Regulatory capture refers to the process by which a regulatory agency, created to act in the public interest, instead advances the commercial or political interests of the industry it is meant to oversee. The FDA has been cited by academics, journalists, and independent researchers as one of the clearest examples of regulatory capture in the United States.

Key structural factors include:

  • The Prescription Drug User Fee Act (PDUFA), first passed in 1992, requires pharmaceutical companies to pay fees directly to the FDA to fund drug review processes. Critics argue this creates a de facto client relationship between the regulator and the regulated.
  • The revolving door: numerous senior FDA officials have taken lucrative positions at pharmaceutical companies following their tenure at the agency, and vice versa. Former FDA Commissioner Scott Gottlieb, for example, joined the board of Pfizer shortly after leaving the agency.
  • Internal whistleblowers have on multiple occasions alleged that scientific dissent within the FDA is suppressed when findings conflict with industry-sponsored data.

Dr. David Martin, a researcher who has investigated patent trails related to coronavirus technologies, has argued that the institutional relationships between the FDA, the NIH, and major pharmaceutical corporations represent a form of coordinated regulatory management rather than independent oversight. Dr. Reiner Füllmich, a German-American attorney who convened a series of evidentiary hearings into COVID-19 countermeasures, similarly cited FDA approval processes as evidence of systemic institutional failure and potential fraud.

The concept of regulatory capture is well-documented in mainstream academic literature (see Stigler, 1971), but its application to the FDA's handling of COVID-era products remains contested in official discourse, even as internal documents released under Freedom of Information Act (FOIA) requests have raised substantive questions.

See also: Regulatory Capture, Anthony Fauci, WHO

COVID-19 Vaccine Authorisations

The FDA's handling of COVID Vaccines during the 2020–2022 period generated significant controversy, both from within the scientific community and among the broader public.

Emergency Use Authorisation (EUA)

Rather than undergoing the standard Biologics License Application (BLA) process — which typically requires multi-year clinical trials, independent safety monitoring, and long-term follow-up data — the COVID-19 vaccines were initially authorised under an Emergency Use Authorisation (EUA). Under this pathway:

  • Full safety and efficacy data from completed trials is not required.
  • Long-term adverse event data is not required prior to authorisation.
  • The standard comparator requirement can be modified.
  • Recipients must technically be informed that the product is authorised, not fully approved — a requirement that was frequently not communicated to the public.

The EUA pathway is designed for genuine emergencies where no adequate alternatives exist. Critics — including many academic physicians and former FDA scientists — argued that the existing treatments under investigation (see below) disqualified the emergency threshold.

Full Approval and Ongoing Questions

The Pfizer-BioNTech vaccine received full FDA approval (under the name Comirnaty) in August 2021. However, critics noted that Comirnaty was not immediately or widely available as the approved product, and that the EUA product continued to be administered — a distinction with significant legal implications regarding Bodily Autonomy and Bodily Autonomy Legislation.

The FDA's accelerated review process, compressed trial periods, and the limited data available at the time of authorisation remain subjects of ongoing independent investigation. Key concerns include the role of Lipid Nanoparticles as delivery vectors and the implications of mRNA Technology for long-term genomic stability — areas where the FDA's pre-authorisation data requirements were substantially reduced compared to standard biological products.

Nanomaterial Disclosure Failures

One of the most serious allegations levelled at the FDA concerns its alleged failure to require full disclosure and independent testing of nanomaterial components present in pharmaceutical products, including COVID-19 vaccines.

Dr. Ana Maria Mihalcea, a physician and researcher specialising in nanoparticle biology, has published findings and clinical observations suggesting the presence of self-assembling structures in COVID-19 vaccine vials and in the blood of vaccinated individuals. She argues that the FDA's regulatory framework was not designed to — and did not — adequately evaluate these components.

Dr. Pablo Campra, a Spanish materials scientist, conducted independent microscopy analysis of COVID-19 vaccine vials and alleged the presence of Graphene Oxide and other nanomaterials not declared in official ingredient lists. His findings have not been replicated by regulatory bodies, but neither have they been formally and transparently investigated by the FDA.

Broader concerns include:

  • The absence of mandatory pre-market testing for nanoparticle biodistribution and long-term tissue accumulation in FDA vaccine review guidelines.
  • The FDA's guidance documents on nanotechnology, while existing, are largely voluntary and lack enforcement mechanisms.
  • Allegations that Self-Assembling Nanostructures present in certain formulations fall outside existing regulatory categories entirely, meaning they were never subject to specific safety evaluation.

These concerns intersect with research documented elsewhere in this wiki under Intra-Body Nano Network, Nanoparticles in Vaccines, and Biosurveillance.

Suppression of Alternative Treatments

During the COVID-19 pandemic, the FDA took active steps to restrict or discourage the use of several off-patent treatments that some physicians and researchers were reporting as effective:

  • Ivermectin: The FDA issued public guidance explicitly advising against the use of ivermectin for COVID-19, including a widely circulated post stating "You are not a horse." This guidance was subsequently challenged in federal court, and the FDA was ordered to remove some of its anti-ivermectin social media content. Critics argue that the agency acted beyond its legal authority in discouraging a legal, prescribed, off-patent medication.
  • Hydroxychloroquine (HCQ): The FDA initially granted an EUA for hydroxychloroquine for COVID-19 treatment in March 2020, then revoked it in June 2020 following a disputed Lancet study (which was itself later retracted). Independent researchers have argued that the FDA's handling of HCQ was inconsistent and appeared to track political rather than purely scientific considerations.

The significance of this pattern, according to critics including Dr. Reiner Füllmich and independent physician networks, is that an EUA for vaccines legally requires the absence of adequate, approved alternatives. Some researchers argue that the suppression of existing treatments was therefore not merely a medical policy decision but a prerequisite for maintaining the legal basis of vaccine emergency authorisations.

This has implications for Bodily Autonomy Legislation and the broader question of whether individuals had genuine informed consent when no legal alternatives were acknowledged as available.

Related Pages

See Also

Retrieved from "https://nanoworldorder.com/wiki/index.php?title=FDA&oldid=1814"